Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Practical aspects of building a new immunotherapy program: the future of cell therapy.

Literature DB >> 33275680

Practical aspects of building a new immunotherapy program: the future of cell therapy.

Abstract

Cellular-redirecting therapies, including bispecific T-cell engagers and chimeric antigen receptor (CAR) T cells, are rapidly changing the treatment landscape of hematologic malignancies and solid tumor malignancies. I will discuss the unique safety profile and logistical aspects that pose challenges and opportunities for the safe and successful delivery of these therapies. Close interaction, communication, and established partnerships between the primary oncologist, the disease specialist, and the immune effector cell provider will be needed to provide optimal care longitudinally for any patient. I will discuss practical ways for any program to deliver these therapies and how future advances may widen availability beyond just a few centers.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2020 PMID： 33275680 PMCID： PMC7727545 DOI： 10.1182/hematology.2020000144

Source DB: PubMed Journal: Hematology Am Soc Hematol Educ Program ISSN： 1520-4383

21 in total

Review 1. Adult Survivorship: Considerations Following CAR T-Cell Therapy.

Authors: Joaquin Buitrago; Sherry Adkins; Misha Hawkins; Kharington Iyamu; Teresa Oort
Journal: Clin J Oncol Nurs Date: 2019-04-01 Impact factor: 1.027

2. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

Authors: Enli Liu; David Marin; Pinaki Banerjee; Homer A Macapinlac; Philip Thompson; Rafet Basar; Lucila Nassif Kerbauy; Bethany Overman; Peter Thall; Mecit Kaplan; Vandana Nandivada; Indresh Kaur; Ana Nunez Cortes; Kai Cao; May Daher; Chitra Hosing; Evan N Cohen; Partow Kebriaei; Rohtesh Mehta; Sattva Neelapu; Yago Nieto; Michael Wang; William Wierda; Michael Keating; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal: N Engl J Med Date: 2020-02-06 Impact factor: 91.245

Review 3. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors: Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal: Nat Rev Clin Oncol Date: 2017-09-19 Impact factor: 66.675

4. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors: Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245

5. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Authors: David T Teachey; Michael R Bishop; David G Maloney; Stephan A Grupp
Journal: Nat Rev Clin Oncol Date: 2018-02-13 Impact factor: 66.675

6. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA⁺ Metastatic Colorectal Cancers.

Authors: Chengcheng Zhang; Zhe Wang; Zhi Yang; Meiling Wang; Shiqi Li; Yunyan Li; Rui Zhang; Zhouxing Xiong; Zhihao Wei; Junjie Shen; Yongli Luo; Qianzhen Zhang; Limei Liu; Hong Qin; Wei Liu; Feng Wu; Wei Chen; Feng Pan; Xianquan Zhang; Ping Bie; Houjie Liang; Gabriele Pecher; Cheng Qian
Journal: Mol Ther Date: 2017-03-31 Impact factor: 11.454

7. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors: Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal: N Engl J Med Date: 2018-02-01 Impact factor: 91.245

8. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors: David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: Cancer Discov Date: 2016-04-13 Impact factor: 39.397

Review 9. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.

Authors: Jie Liu; Guangyu Zhou; Li Zhang; Qi Zhao
Journal: Front Immunol Date: 2019-03-19 Impact factor: 7.561

Review 10. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.

Authors: Katayoun Rezvani; Sattva S Neelapu; Elizabeth J Shpall; Kris M Mahadeo; Sajad J Khazal; Hisham Abdel-Azim; Julie C Fitzgerald; Agne Taraseviciute; Catherine M Bollard; Priti Tewari; Christine Duncan; Chani Traube; David McCall; Marie E Steiner; Ira M Cheifetz; Leslie E Lehmann; Rodrigo Mejia; John M Slopis; Rajinder Bajwa; Partow Kebriaei; Paul L Martin; Jerelyn Moffet; Jennifer McArthur; Demetrios Petropoulos; Joan O'Hanlon Curry; Sarah Featherston; Jessica Foglesong; Basirat Shoberu; Alison Gulbis; Maria E Mireles; Lisa Hafemeister; Cathy Nguyen; Neena Kapoor
Journal: Nat Rev Clin Oncol Date: 2019-01 Impact factor: 66.675

1 in total

Review 1. Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.

Authors: Praveen Ramakrishnan Geethakumari; Dheepthi Perumal Ramasamy; Bhagirathbhai Dholaria; Jesús Berdeja; Ankit Kansagra
Journal: Curr Hematol Malig Rep Date: 2021-06-05 Impact factor: 3.952